Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of FAB122 (edaravone) in amyotrophic lateral sclerosis
2022-003050-32Phase 3Terminated
- Sponsor
- Ferrer
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of edaravone in amyotrophic lateral sclerosis (ALS), sponsored by Ferrer. Primary endpoint: Treatment emergent adverse events. Started Nov 2022; status: terminated.
02
Drugs
edaravone
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2022-003050-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003050-32.